Compound ID | 2978
Class: DNA synthesis inhibitor
| Details of activity: | Active against Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii; Gyrase B inhibitor |
| Description: | Synthetic compound; aminobenzimidazole; active against Mycobacterium tuberculosis within macrophages; prodrug has improved solubility rapidly converted to active compound |
| Institute where first reported: | Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA |
| Year first mentioned: | 2015 |
| Development status: | Experimental |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/57524959 |
| Guide to Pharmacology: | SPR719 |
| Citations: |
|